CA-CHARGEPOINT-HOLDINGS
5.10.2022 09:01:38 CEST | Business Wire | Press release
ChargePoint Holdings, Inc. (NYSE: CHPT), a leading electric vehicle (EV) charging network, today announced the launch of the CP6000, ChargePoint’s most flexible and serviceable global AC EV charging solution now available for vehicles of all types and sizes.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221005005038/en/
(Photo: Business Wire)
Designed for the needs of the European market, the CP6000 is a complete charging solution for businesses and fleets that want to confidently and efficiently prepare for the future of electric mobility. Seamlessly integrating network software, station hardware and customer support, the CP6000 is designed to prepare businesses of all kinds across the globe for the next wave of EV adoption. The CP6000 is designed for scalability, flexibility, reliability, and a best-in-class driver experience, and offers reliable AC charging for 1 or 3 phase power at an adaptable output of 3.7 to 22kw per port.
“ChargePoint’s mission is to make the transition to electric mobility simple. As the result of ChargePoint’s experience shaping the charging industry over the past 15 years, we understand what is critical to station owners and drivers, including effortless charging experiences, scalable design, quality products and excellent service,” stated ChargePoint Chief Product Officer, Bill Loewenthal. “EV charging needs are universal, even if what and how we drive varies by geography. The CP6000 has been designed across our R&D facilities in North America and Europe to cater to the charging needs of businesses, fleets and EV drivers. Built on our decade-plus of experience serving EV drivers and all types of organisations, CP6000 has what businesses need to be part of the future of electric mobility.”
Superior driver experience
Whether charging is for employees, customers, visitors or a fleet, the driver is at the centre of it all, which is why the driver is at the centre of the CP6000 design. The top-rated ChargePoint app has over 200,000 active places to charge on its network globally, as well an additional 355,000 public places to charge through roaming integrations with other major networks. ChargePoint driver support is available in multiple languages, ensuring drivers across Europe receive the best experience possible. The addition of the CP6000 to ChargePoint’s network ensures drivers are easily able to find, use and pay for the charge they need, in the language and currency they prefer.
“The new CP6000 series is a great addition to an already strong contingent of reliable, software driven hardware we offer our clients,” stated Bruce Galliford, CEO at RAW Charging, one of the first customers to receive the new technology. “When ChargePoint expanded to Europe, we saw a company with the longevity, customer base, engineering prowess and experience to be a fit with our vision. Leaving the technology to ChargePoint, we can focus on deployment. We have more projects coming for Aviva Investors, Greene King, McArthurGlen and other customers. We’re currently planning strategic expansion across Europe working with organisations that have a portfolio of sites across the continent. This year we’ll be putting in four new sites per working day, and when you’re doing that, you want it to work flexibly and at scale.”
Part of ChargePoint's unified software platform
The CP6000 works seamlessly with ChargePoint’s software platform, which offers real-time visibility into revenue, energy costs and driver details, complete control over pricing and driver access, and actionable reporting with over 35 pre-built charts and reports. ChargePoint’s software also includes robust power management tools to automatically reduce energy costs, on-station video messages, and over 40 turnkey API integrations. The CP6000 is also fully compliant with Open Charge Point Protocol (OCPP) 2.01, the latest version of the open standard. Together, these features make it easy for customers to manage their charging program, reduce costs, improve utilisation, and prepare for the future.
Built for the future of electrification
ChargePoint believes demand for EV charging is poised for rapid growth. The CP6000 series’ modular design and forward-thinking technology supports flexible configurations and easy upgrades, making it the robust solution for scaling EV charging availability and maximising station value. It can be customised into dozens of configurations for multiple use cases or regions, offering options on sockets, cable management, branding, display, shuttering and more. This modularity allows the CP6000 to more easily support field replacements and service, while also offering advanced sensors for enhanced diagnostics and support.
The CP6000 has also been designed to operate on Europe's variety of power grids and regulations. For example, the CP6000 meets the UK government's requirements for contactless payment capabilities for all AC stations of 7.1kW and above.
The CP6000 is now available to order across dozens of ChargePoint operating countries. To learn more about deploying the CP6000 across your business, contact your ChargePoint sales representative or distributor.
About ChargePoint
ChargePoint is creating a new fueling network to move people and goods on electricity. Since 2007, ChargePoint has been committed to making it easy for businesses and drivers to go electric with one of the largest EV charging networks and a comprehensive portfolio of charging solutions available today. The ChargePoint cloud-based subscription platform and software-defined charging hardware are designed to include options for every charging scenario from home and multifamily to workplace, parking, hospitality, retail and transport fleets of all types. Today, one ChargePoint account provides access to hundreds of thousands of places to charge in North America and Europe. To date, more than 133 million charging sessions have been delivered, with drivers plugging into the ChargePoint network on average every second. For more information, visit the ChargePoint pressroom, the ChargePoint Investor Relations site, or contact ChargePoint’s North American or European press offices or Investor Relations.
CHPT-IR
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221005005038/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
